General MedicationsORALGeneric
LABID
THEOPHYLLINE
Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary
Approval overview LABID is listed in Drugs@FDA under application 087225 (ANDA).
Marketing status: Discontinued Active ingredient THEOPHYLLINE Form and strength TABLET, EXTENDED RELEASE;ORAL - 250MG Sponsor WARNER CHILCOTT Submission history See approval history documents.
Structured Monograph
Clinical summary
Approval overview LABID is listed in Drugs@FDA under application 087225 (ANDA). Marketing status: Discontinued Active ingredient THEOPHYLLINE Form and strength TABLET, EXTENDED RELEASE;ORAL - 250MG Sponsor WARNER CHILCOTT Submission history See approval history documents.
Monitoring
- • Marketing status: Discontinued
Interaction Notes
- No interaction notes stored yet.